VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Biohaven
BHVN
$1.68B
| $107K | 0.06% |
4,460
-1,978
| -31% | -$47.3K |
|
|
MRTX
352
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $107K | 0.06% |
2,952
+634
| +27% | +$22.9K |
|
353
Nuvalent
NUVL
$5.83B
| $106K | 0.06% |
2,524
-603
| -19% | -$25.4K |
|
354
ImmunityBio
IBRX
$2.27B
| $105K | 0.06% |
37,888
+22,879
| +152% | +$63.6K |
|
355
Cassava Sciences
SAVA
$104M
| $105K | 0.06% |
4,293
+2,005
| +88% | +$49.2K |
|
356
ATAI Life Sciences
ATAI
$980M
| $105K | 0.06% |
61,089
+28,450
| +87% | +$48.9K |
|
|
INBX
357
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $105K | 0.06% |
4,044
+606
| +18% | +$15.7K |
|
358
Immatics
IMTX
$761M
| $105K | 0.06% |
9,088
-1,382
| -13% | -$15.9K |
|
359
Novavax
NVAX
$1.28B
| $105K | 0.06% |
14,085
+8,212
| +140% | +$61K |
|
360
Protagonist Therapeutics
PTGX
$3.77B
| $105K | 0.06% |
3,786
-6,500
| -63% | -$180K |
|
361
Syndax Pharmaceuticals
SNDX
$1.47B
| $104K | 0.06% |
4,983
+863
| +21% | +$18.1K |
|
|
MORF
362
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $104K | 0.06% |
1,818
-1,864
| -51% | -$107K |
|
|
BCYC
363
Bicycle Therapeutics
BCYC
$496M
| $104K | 0.06% |
4,074
+929
| +30% | +$23.7K |
|
364
Vaxcyte
PCVX
$4.29B
| $104K | 0.06% |
2,075
-136
| -6% | -$6.79K |
|
365
CRISPR Therapeutics
CRSP
$4.99B
| $104K | 0.06% |
1,844
-173
| -9% | -$9.71K |
|
|
SWTX
366
DELISTED
SpringWorks Therapeutics
SWTX
| $103K | 0.06% |
3,946
-368
| -9% | -$9.65K |
|
367
Prothena Corp
PRTA
$460M
| $103K | 0.06% |
1,513
-230
| -13% | -$15.7K |
|
|
ITOS
368
DELISTED
iTeos Therapeutics
ITOS
| $103K | 0.06% |
7,773
+2,991
| +63% | +$39.6K |
|
369
IDEAYA Biosciences
IDYA
$2.38B
| $103K | 0.06% |
4,378
-1,594
| -27% | -$37.5K |
|
370
Vir Biotechnology
VIR
$732M
| $103K | 0.06% |
4,179
+274
| +7% | +$6.72K |
|
371
Xencor
XNCR
$610M
| $102K | 0.06% |
4,097
+552
| +16% | +$13.8K |
|
372
Ventyx Biosciences
VTYX
$180M
| $102K | 0.06% |
3,103
+123
| +4% | +$4.03K |
|
373
Cytokinetics
CYTK
$6.34B
| $101K | 0.06% |
3,106
+661
| +27% | +$21.6K |
|
374
Arbutus Biopharma
ABUS
$805M
| $101K | 0.06% |
44,024
+6,827
| +18% | +$15.7K |
|
|
CERE
375
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $101K | 0.06% |
3,182
-578
| -15% | -$18.4K |
|